Companies: 10,795·Total market cap: $144.5T
Nascent Biotech, Inc.

Nascent Biotech, Inc.

NBIOOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$68887
P/E Ratio
52W High$0.1345
52W Low$0.0001
Overview

Nascent Biotech, Inc. (NBIO) Revenue

Annual & quarterly revenue history · segment & region breakdown

NBIO · revenue · updated Jun 10, 2026

Core revenue metrics

Nascent Biotech, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.00B
4-quarter sum · USD
YoY growth
+0.00%
vs FY
Price / sales
mktCap ÷ TTM rev
Revenue per day
Est. TTM ÷ 365
Revenue / employee
0 employees
FY
FY
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · Nascent Biotech, Inc. SEC filings · GAAPUpdated: 2026-06-10

Revenue trend

· Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
NBIO revenue by year · NBIO revenue history · NBIO annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Nascent Biotech, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Nascent Biotech, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Nascent Biotech, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

NBIO revenue · 4 questions

NBIO's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.

NBIO revenueNBIO annual revenuewhat is NBIO revenueNBIO TTM revenue

Source: FMP · Nascent Biotech, Inc. SEC filings · GAAP · Nascent Biotech, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026